QUEST DIAGNOSTICS INC DGX

Quest Diagnostics' latest hard evidence is the SEC financial rail for the quarter ending 2026-03-31: $2.90B of revenue from contracts with customers, $399.0M of operating income, $252.0M of net income attributable to parent and diluted EPS of $2.24. That gives the DGX story a practical centre of gravity: this is an operating diagnostics business being measured by filed revenue, income, cash and investment, not by a loose market mood.

The official issuer rail describes Quest as the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. It also states that Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories providing HIPAA-covered services. That matters because the company story is not abstract software or a pure financial wrapper. It is laboratory work, health-data handling and service delivery, where scale only counts if the results, compliance and customer-facing systems keep working.

The filed balance-sheet and cash-flow facts keep the story grounded. At 2026-03-31, Quest reported $16.67B of assets, $7.37B of stockholders' equity attributable to parent, $393.0M of cash and cash equivalents, $225.0M of inventory and $278.0M of net cash provided by operating activities. Payments to acquire property, plant and equipment were $114.0M. Those figures show a cash-generating business that still has to fund the physical and technical base behind the testing network.

The supplied source rail includes SEC EDGAR filings, SEC submissions JSON, SEC companyfacts JSON and the official issuer website, but it does not include a chart route or live TradingView context. That limits this daily layer in a useful way: no invented candle levels, no support line theatre, no pretend read on price action. The market mechanism here is the public equity wrapper around a diagnostics operator, with the current file driven by filings and official company identity rather than a supplied price chart.

The named recent developments are filing events rather than commercial announcements: an 11-K dated 2026-06-18, Form 4 filings dated 2026-06-08, 2026-06-02 and 2026-05-21, Form 144 notices dated 2026-06-04 and 2026-06-01, and 8-K pages dated 2026-05-21, 2026-05-08 and 2026-05-01. The rail proves those official pages exist; it does not, from the supplied facts alone, parse a new product, guidance change, acquisition detail or share-price reaction.

The tension is therefore clean: DGX has a substantial filed operating base, an official laboratory-services identity and a busy recent filing trail, but this evidence pack does not supply a fresh management quote, segment breakout, live valuation, dividend fact, buyback figure or chart setup. A deeper file would need those items before making any claim about market repricing, growth mix or capital-return optics.